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re-use of eDiaries previously used by patients doing fingerstick tests poses a low and 
acceptable risk; flexibility for handling measurements should be incorporated in the 
eDiary design including batch and individual reporting, reporting hypoglycaemic 
events as part of a meal event or as a standalone event and edit checks should be 
included to identify where a number of low measurements relate to the same event; 
there should be clear guidance to patientson how to transfer measurements to the 
eDiary; a method for managing control test measurementsshould be incorporated; 
and integrating glucometer measurements decreases patient burden and increases 
patient engagement.
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The DeveloPmenT of an InTegraTeD ecoa SoluTIon To ImProve The 
QualITy of DaTa caPTure In DIaBeTeS clInIcal TrIalS
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Objectives: The 347 million people who live with diabetes face an array of daily 
disease management tasks, e. g. measuring blood glucose, keeping track of the nutri-
tional value of meals, and monitoring insulin usage. Diabetes trials vary in method-
ology, level of patient burden, volume of data captured and patient compliance. Our 
aim was to develop an electronic data capture system for use in clinical trials which 
would decrease patient burden while increasing compliance and improving data 
quality. MethOds: We developed a diabetes specific, electronic, event driven diary 
for capturing data relevant for clinical trials. Iterations of the diary were tested in 
diabetes patients via focus groups and one-on-one usability evaluations. Feedback 
was analysed to understand the typical day-to-day experience of living with diabe-
tes, and to examine the impact and acceptability of a tailored electronic solution. 
Feedback was incorporated into a refined solution for use in clinical trials. Results: 
The nature of diabetes means that patients are typically very actively engaged in 
managing their disease, although a lot of variation was seen in patients and their 
management routines. The requirement for multiple devices and high volume of 
data was also reported as burdensome. The focus groups and usability studies high-
lighted the benefit of providing a flexible solution, as well as redesigning the diary 
from unstructured blood glucose measurement reporting to event driven reporting. 
This redesign met the needs of patients, as well as the requirements of clinical trial 
protocols. Patients agreed that they would prefer this integrated, intuitive solution 
over traditional paper and electronic solutions. cOnclusiOns: When faced with 
the task of recording patient data in diabetes, a well-designed and thoroughly tested 
electronic solution can reduce burden and increase patient satisfaction. This in turn 
improves compliance, data quality and overall study efficiency, while meeting the 
needs of all stakeholders.
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Objectives: Treatments for Type 2 Diabetes Mellitus (T2DM) are associated with 
varying effectiveness and safety profiles. Patients’ preferences for each of the medi-
cation characteristics that yield these varying profiles can be assessed through 
discrete choice experiments (DCEs). This study expands on the knowledge from 
two previous T2DM DCE studies conducted in the United Kingdom (UK) and the 
United States (US), and was aimed at evaluating the relative importance of medi-
cation attributes that influence medication choice among participants with T2DM 
from Germany. MethOds: A web-based DCE was conducted among patients with 
self-reported T2DM from Germany. The DCE was designed to examine 7 attributes 
of T2DM medications (efficacy, urinary tract infection/genital infection side effects, 
nausea/other gastrointestinal side effects, weight change, and hypoglycemic events, 
treatment in case of low blood sugar, and blood pressure). Part-worth utilities were 
estimated using multi-logit models, and relative importance [RI] values were cal-
culated for each attribute. Results: N= 600 Participants with T2DM completed the 
study (50% male; mean age= 58.2 years SD= 10.0; BMI= 32.4, SD= 6.8). The RI values 
for the attributes in order of importance were: treatment in case of low blood sugar 
(22.5%), hypoglycemic events (18.1%), weight change (17.5%), efficacy (15.0%), nau-
sea/other gastrointestinal side effects (12.9%), UTI/genital infection side effects 
(7.9%), and blood pressure (6.0%). cOnclusiOns: The results of this study suggest 
that hypoglycemic events and the interventions required in the case of such events 
are of great importance to patients; these two attributes represent over 40% of the 
variance in patients’ medication decisions. Change in body weight as a consequence 
of treatment was also an important attribute to patients. The results may help treat-
ment providers and payers to understand the preferences of patients with T2DM. 
Understanding these preferences may be useful in devising strategies for success-
fully engaging and maintaining patients on T2DM treatments.
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Objectives: Hypoglycaemia is the main side-effect of insulin therapy and can 
prevent optimal diabetes management. Real-world data on the frequency and 
impact of non-severe (self-treated) hypoglycaemic events are scarce. Self-reported 
frequency of non-severe hypoglycaemic events (NSHEs), their impact on personal 
well-being, work productivity and health care resource use, and patient–physician 
communication following non-severe events, were examined in people taking insu-
lin. MethOds: Adults in the UK aged > 15 years with Type 1 or insulin-treated Type 2 
diabetes mellitus (T1DM or T2DM) completed ≤ 4 questionnaires at weekly intervals 
(7-day recall). Severe hypoglycaemic events (requiring external assistance) are not 
more health care provider visits in the past six months (11.7 vs. 8.9) compared with 
matched controls (n= 286) (all p< .05). cOnclusiOns: DME was more commonly 
reported by patients with diabetes and its presence was associated with a significant 
humanistic and economic burden in the 5EU.
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Objectives: Hyponatraemia (HN) is estimated to occur in 15% of all hospitalised 
patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) 
being one of the most common aetiologies. Patients treated with tolvaptan have 
demonstrated improvements in health related quality of life (HRQL) in the SALT I 
& II randomised controlled trials. The objective of this study was to map the SF-12 
responses from SALT I & II to EQ-5D using a publically available algorithm and 
predict the change in EQ-5D associated with tolvaptan. MethOds: SF-12 scores 
from the pooled SALT I & II studies were converted to EQ-5D scores using a map-
ping algorithm developed by Gray, et. al 2006. Simulated EQ-5D scores were then 
used to estimate changes in EQ-5D from baseline at day 30 using ordinary least 
squares regression (OLS) as a function of baseline characteristics, treatment arm and 
achievement of sodium correction (NA+) at day 4 (> 135 mmol/l). A preferred model 
was selected based on the highest adjusted R-squared. Secondary analyses looked 
at change from baseline in EQ-5D at day 7, day 14 and at 7 day follow-up following 
treatment discontinuation. Results: The preferred model included baseline age, 
gender, sodium level, EQ-5D and a tolvaptan indicator variable. Based on this model, 
tolvaptan was associated with a positive increase in simulated EQ-5D of 0.10 (n= 164, 
p= 0.03) at day 30 vs. placebo. After 7 days follow-up, tolvaptan was associated with a 
positive, but non- statistically significant effect of 0.04 (n= 74, p= 0.54). No effect was 
observed at day 7 (n= 76, p= 0.90) or at day 14 (n= 85, p= 0.84). Sodium correction did 
not appear to be a statistically significant predictor of HRQL. cOnclusiOns: The 
preferred model indicated a statistically significant improvement in HRQL associ-
ated with tolvaptan use at day 30. Further research is required to establish whether 
sodium correction has an effect of HRQL.
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Objectives: This 4-wk, Phase 3b, multicentre, open-label, single-arm, outpatient 
study evaluated the safe and effective use of the Single-Use Pen (SUP) in patients 
with type 2 diabetes (T2D) who were naïve to self-injection or injecting others. The 
SUP contains a pre-filled syringe and automates needle insertion, retraction, and 
drug delivery; specifically designed for once-weekly glucagon-like peptide-1 recep-
tor agonist, dulaglutide. Patient-reported outcomes (PROs) related to self-injection 
and to the SUP were important secondary outcomes. MethOds: Patients (N= 211) 
were trained on correct injection technique with the SUP containing 0.5 mL placebo 
prior to initial self-injection. PRO measures were completed by patients after final 
injection or at early termination to evaluate device ease of use, experience (including 
satisfaction/confidence), and key device features. Site trainers rated how easy/dif-
ficult it was to train the patient to use the SUP. Results: 99.0% of patients found the 
device easy to use. Patients found it easy to hold the SUP when injecting and to push 
the button to inject (97.6% and 98.1%, respectively). 97.1% of patients were satisfied 
with the overall injection experience, 96.7% of patients were confident they could 
identify when the full dose was delivered, and 99.0% were confident in their overall 
ability to use the SUP. Patients liked not having to attach (99.0%), touch (98.6%), or see 
(95.7%) the needle. 95.7% of patients also liked hearing the click indicating the dose 
was complete and 94.8% liked the automatic needle insertion. Finally, 92.4% of site 
trainers found it easy to train patients on how to use the SUP. cOnclusiOns: This 
study demonstrated the SUP could be used safely and effectively by injection-naïve 
patients with T2D; PRO results indicated patient satisfaction with the SUP injection 
experience. A positive injection experience may be an important factor for some 
patients and providers when initiating injectable therapy.
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Objectives: Monitoring glycaemic control is important in diabetes clinical trials 
and is also relevant for some oncology trials. It is possible to seamlessly integrate 
blood glucose measurements with clinical trial data via Bluetooth. This integration 
reduces transcription errors and improves accuracy and completeness of data, while 
reducing burden on patients. Our aim was to explore best practices in integrating 
measurements with ePRO. MethOds: A review of best practice and experience in 
blood glucose measurement data integration was undertaken and the findings were 
incorporated into a solution for use in clinical trials. A systematic literature review 
was also undertaken to assess the contamination risk to individuals handling and 
re-using electronic diaries (eDiary) previously used by patients doing fingerstick 
tests for blood glucose measurement. We defined search terms and undertook a 
PubMed and internet search. All documents that were identified as possibly relevant 
were reviewed and summarised. Results: The review revealed key features and 
activities related to planning, design, testing and delivery that are important for 
successful integration of blood glucose measurements with ePRO data. The litera-
ture review confirmed that the risk in handling and re-using eDiaries previously 
used by patients doing fingerstick tests was very low. cOnclusiOns: Handling and 
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Objectives: SAGIT is a clinician-reported outcome tool designed to help endocri-
nologists describe acromegaly patients and disease activity in their everyday prac-
tice. SAGIT records five elements of the disease: Signs and symptoms (S), Associated 
comorbidities (A), GH concentration (G - either assessed as GH nadir after oral glu-
cose tolerance test or GH random or series), IGF-1 concentration (I) and Tumor (T). 
The objectives of the present work were to assess acceptability, understanding 
and possible uses of SAGIT with endocrinologists in real conditions. MethOds: 
Endocrinologists from France (n= 2), Germany (n= 1), Italy (n= 2), Spain (n= 2) and 
United States (n= 2) completed SAGIT for patients with active acromegaly (n= 9), 
controlled/stable acromegaly (n= 10) and treatment-naïve patients (n= 7). After com-
pletion of SAGIT, endocrinologist’s reported their perception and opinion of the tool 
using the PRAgmatic Content and face validity Test. Results: Endocrinologists 
had no difficulties completing the S, A, I and T elements of SAGIT and reporting the 
respective scores based on their patients’ data. Both GH nadir after oral glucose load 
and GH random or series were informed by most endocrinologists while informa-
tion for one of the two elements only is required. The majority of endocrinologists 
deemed the information retrieved from SAGIT useful, either for research purpose 
(n= 7), decision-making (n= 6), or response therapy assessment (n= 5). They found 
it concise, easy to understand and unbiased (n= 8), and simple, quick to complete 
and informative (n= 7). Scores and decision rules and interpretation were among 
the aspects that required improvement. Scores of each elements of SAGIT vary 
according to patient’s acromegaly status. cOnclusiOns: Face and content validity 
of SAGIT are demonstrated, as is its applicability in clinical practice and research. It 
seems a promising tool for staging and classifying acromegaly patients. The planned 
validation study will allow the definition of scoring rules, interpretation and recom-
mendations for managing patients in clinical practice.
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Objectives: To synthesize the available information on the therapeutic value of 
dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 diabetes mellitus 
(T2DM) from the point of view of the patient-reported outcomes (PROs). MethOds: 
A systematic review was performed on International (Pub Med, WOK, Scopus, 
Cochrane Library) and Spanish (IBECS, MEDES) databases. Observational studies and 
narrative or systematic reviews regarding T2DM patients and use of DPP-4 inhibitors 
until June 2013 were selected. Results: We identified 1,713 publications; 317 were 
excluded after duplicate review, 1,383 by title/abstract review and 9 after applying 
inclusion criteria (n= 9). A total of 4 studies conducted in Italy (n= 1), Germany (n= 1), 
USA (n= 1), and one international (including Spain) were selected. Three publications 
had a retrospective design and 1 was prospective. Two studies reported information 
about adherence/persistence, one about satisfaction and one about preferences. No 
information about HRQoL was identified. Patients receiving DPP-4 inhibitors were 
more likely to be adherent than those treated with Glucagon-like peptide-1 (GLP-1) 
agonists [Odds Ratio= 0.40; 95% CI= 0.37-0.42], sulfonylurea [OR= 0.49; 95% CI= 0.46-
0.52] or thiazolidinediones [OR= 0.54; 95% CI= 0.51-0.57]; moreover, DPP-4 inhibitors 
were associated with a lower risk of treatment discontinuation [Hazard Ratio= 0.74; 
95% CI= 0.71-0.76], explained by a greater tolerability and a lower risk of hypoglyce-
mia. Combination of DPP-4 inhibitors and metformin increased patient’s satisfac-
tion by a 30%, associated with higher control of glucose levels. Most of the patients 
preferred DPP-4 inhibitors to GLP-1 agonists (85% vs. 15%; p< 0.001) as first option. In 
the Spanish population, the proportion of patients preferring DPP-4 inhibitors was 
even higher (90.4% vs. 9.6%; p< 0.001). cOnclusiOns: PROs in DPP-4 inhibitors are 
poorly described in the literature. Nevertheless DPP-4 inhibitors are preferred as first 
option and are associated with higher persistence and satisfaction, mainly due to 
higher perception of glycemic control of glucose level and lower hypoglycemia risk.
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Objectives: The objective of the study is to assess the cost of continuous sub-
cutaneous insulin infusion (CSII) application for children with diabetes type 1 in 
Sofia, Bulgaria and to compare the changes in BMI and HbA (1c), of three groups of 
children- with diabetes – applying insulin pens with human insulin, with analog 
insulin and children with insulin pumps. MethOds: The study was performed from 
the point of view of the health insurance fund and patients. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Cost of CSII, blood glucose monitoring system and strips was 
calculated. The primary outcome observed was the variation in HbA (1c) and the 
secondary was the BMI change. 51 children were observed. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Results: The total yearly cost weighed with the duration of 
the disease is 1850 Euro (30% reimbursed). The average improvement of HbA (1c) 
after the CSII introduction is 1.72 and the average BMI was 37.03. cOnclusiOns: 
Improvements in glycemic control associated with CSII led to reduced HbA (1c) 
reported here. Results: Overall, 1,038 respondents (T1DM= 466, T2DM= 572) com-
pleted 3,528 questionnaires. Mean insulin treatment duration was 11.7 years and 
mean HbA1c was 8.2% (66.2 mmol/mol). Mean NSHE/week was 2.4 (T1DM) and 0.8 
(T2DM); 23% (T1DM) and 26% (T2DM) occurred at night. Fatigue and reduced alert-
ness were the commonest sequelae of NSHEs (78% and 51% of respondents, respec-
tively). Effects of nocturnal NSHEs lasted significantly longer than effects of daytime 
events: T1DM= 10.6 vs. 4.9 hours (p= 0.0002); T2DM= 15.3 vs. 5.1 hours (p< 0.0001). 
In the week following a NSHE, blood glucose testing increased 12% (T1DM) and 
21% (T2DM). In employed respondents (47% of total), 20% of NSHEs caused loss of 
work-time, which was longer following nocturnal NSHEs: T1DM= 2.7 vs. 1.1 hours 
(p= 0.0184); T2DM= 2.5 vs. 1.6 hours (p= 0.1340). Over a third of employed respond-
ents experienced difficulty concentrating at work following NSHEs (T1DM= 39%; 
T2DM= 44%). Respondents contacted a health care professional (HCP) after 3% 
(T1DM) and 7% (T2DM) of NSHEs. Overall, respondents rarely or never informed 
HCPs about NSHEs (T1DM= 82%; T2DM= 69%). cOnclusiOns: NSHEs are common 
in adults with insulin-treated diabetes in the UK, and have a negative impact on 
personal well-being, work productivity, and health care resource use. As they are 
seldom reported to HCPs, the burden of hypoglycaemia may be underestimated.
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Objectives: The aim of the empirical study is to evaluate patients’ preferences for 
different characteristics of treatment in type2 diabetes mellitus (T2DM). As T2DM 
treatment asks for strict adherence, patient’s needs and preferences should be taken 
into consideration. MethOds: Based on a qualitative and quantitative analysis 
a Discrete Choice Experiment (DCE) was applied to identify patient preferences. 
Apart from six identical attributes (adjustment of glycated hemoglobin [HbA1c], 
prevention of hypoglycemia, risk of genital infection, risk of gastrointestinal prob-
lems, risk of urinary tract infection and weight change) one continuous variable of 
either healthy life years equivalents (HYE) or money equivalents (ME) was included. 
The DCE was conducted using a fractional factorial design and the statistical data 
analysis used random effect logit models. Results: In total N= 626 (N= 318 HYE + 
N= 308 ME) T2DM patients participated in the survey. The estimation revealed a clear 
dominance for prevention of hypoglycemia (coefficient: 0,937) and adjustment of 
HbA1c (coefficient: 0,541). The attributes, additional healthy life years (coefficient: 
0,458) or additional cost (coefficient: 0,420) were in the middle rank and both of 
significant impact. The side effects, risk of genital infection (coefficient: 0,301), risk 
of gastrointestinal problems (coefficient: 0,296) and risk of urinary tract infection 
(coefficient: 0,241) followed in this order. Possible weight change (coefficient: 0,047) 
was of less importance (last rank) to the patients in this evaluation. cOnclusiOns: 
These survey results demonstrate how much a treatment characteristic of a (hypo-
thetical) oral diabetes treatment affects the treatment decision Understanding how 
patients perceive and value different aspects of oral T2DM treatment is vital to the 
optimal design and evaluation of treatment options. (IB 209403011/14).
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Objectives: Only a few studies have explored deriving clinically relevant time-
equivalents in comparison to money-equivalents from Discrete-Choice Experiment 
(DCE) data. By separating the decision model and including a) healthy life-years 
equivalents (HYEsurvey) or b) money equivalents (MEsurvey) it could be derived 
if both lead to similar preference patterns and allow answering the question: Can 
HYE or ME serve as identical “currency” for patients with type2 diabetes mellitus 
(T2DM) patients? MethOds: A DCE, separated into two versions, was applied to 
identify patient preferences in oral diabetes treatment. Six identical attributes and 
one continuous variable of either HYE or ME were included. To be able to test the 
rescaling effect a scope test has been included, by using different level ranges of 
the time/money attribute. DCE used a fractional factorial design and random effect-
logit-models (Stata, xtlogit and gllamm). Results: The estimation of the N= 626 
(N= 318HYE+N= 308ME) datasets of T2DM patients revealed similar preference pat-
terns for both survey version were prevention of hypoglycemia (coefficient. HYE: 
0,937; coefficient. ME: 0,847) and adjustment of hemoglobin A1c (HbA1c) (coefficient. 
HYE: 0,541; coefficient. ME: 0,649) occurred on first rank. Additional healthy life years 
(coefficient. HYE: 0,458) or additional cost (coefficient. ME: 0,420) ranked in middle 
positions. Side effects of risk of genital infection (coefficient. HYE: 0,301; coefficient. 
ME: 0,416), risk of gastrointestinal problems (coefficient. HYE: 0,296; coefficient. ME: 
0,408) and risk of urinary tract infection (coefficient. HYE: 0,241; coefficient. ME: 
0,355) followed accordingly. Possible weight change (coefficient. HYE: 0,047; coef-
ficient. ME: 0,067) showed no significant effect in this evaluation. cOnclusiOns: 
For the first time the methods of HYE and ME were used in one study to be able to 
compare patients’ preferences regarding those two continuous currencies (HYE/
ME) of treatment in T2DM, as well as the influence of those criteria on the patient 
decision patterns and patient benefit. Therefore, as HYE and ME led to comparable 
preference patterns, both can be discussed as summary measures of health out-
come, in interchangeable ways, but further research is needed. (IB 209203011/14)
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